Amneal Pharmaceuticals, Inc.AMRXNASDAQ
Loading
SG&A Expense Growth Under PressureDecelerating
Percentile Rank45
3Y CAGR+4.2%
5Y CAGR-3.8%
Year-over-Year Change
Year-over-year SG&A expense growth
3Y CAGR
+4.2%/yr
vs -46.2%/yr prior
5Y CAGR
-3.8%/yr
Recent acceleration
Acceleration
+50.3pp
Accelerating
Percentile
P45
Within normal range
vs 5Y Ago
0.8x
Contraction
Streak
1 yr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| 2025 | 10.58% |
| 2024 | 10.88% |
| 2023 | 7.50% |
| 2022 | 9.36% |
| 2021 | 11.87% |
| 2020 | 12.82% |
| 2019 | 25.67% |
| 2018 | 111.32% |
| 2017 | -8.18% |
| 2016 | 8.28% |